person · Reporting owner

Schneeberger Daniel

Disclosed activity across 6 companies

Tapewire entity: 981
SEC CIK: 0001861120

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617	Chief Executive Officer	May 06, 2021	May 07, 2021
InMed Pharmaceuticals Inc.INM · Entity 8139	10% owner	October 06, 2026	October 08, 2026
NextCure, Inc.NXTC · Entity 7461	10% owner	July 30, 2026	August 03, 2026
Rallybio CorpRLYB · Entity 6838	10% owner	May 18, 2026	May 21, 2026
TENAX THERAPEUTICS, INC.TENX · Entity 979	10% owner	September 03, 2026	September 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anebulo Pharmaceuticals, Inc.

Report date May 06, 2021 · Filed May 07, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	982,500	Reported balance Holding disclosure · report date 2021-05-06 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 982,500 F1: Consists of 245,622 shares of restricted common stock issued pursuant to the terms of Dr. Schneeberger's employment agreement with Anebulo Pharmaceuticals, Inc., which vest in equal quarterly installments from August 1, 2020 to November 1, 2021. In addition, includes additional shares of restricted common stock which vest upon achieving certain performance targets as follows: (i) 245,622 shares upon the first patient being dosed in a Phase 2 clinical trial with ANEB-001 and (ii) 245,622 shares upon the availability of a newly synthesized active pharmaceutical ingredient acceptable for dosing in a U.S. clinical trial. Dr. Schneeberger also reflects 245,634 shares that vest upon completion of Anebulo Pharmaceuticals, Inc.'s initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of 245,622 shares of restricted common stock issued pursuant to the terms of Dr. Schneeberger's employment agreement with Anebulo Pharmaceuticals, Inc., which vest in equal quarterly installments from August 1, 2020 to November 1, 2021. In addition, includes additional shares of restricted common stock which vest upon achieving certain performance targets as follows: (i) 245,622 shares upon the first patient being dosed in a Phase 2 clinical trial with ANEB-001 and (ii) 245,622 shares upon the availability of a newly synthesized active pharmaceutical ingredient acceptable for dosing in a U.S. clinical trial. Dr. Schneeberger also reflects 245,634 shares that vest upon completion of Anebulo Pharmaceuticals, Inc.'s initial public offering.

InMed Pharmaceuticals Inc.

Report date October 06, 2026 · Filed October 08, 2026

Jointly reported with ADAR1 Capital Management, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	945,924	Last balance in matching sequence After 2026-10-08 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-10-06 · Purchase · Acquired 5,601 · Balance 940,622 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 2 · 2026-10-07 · Purchase · Acquired 3,046 · Balance 943,668 F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 3 · 2026-10-08 · Purchase · Acquired 2,256 · Balance 945,924 F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

NextCure, Inc.

Report date July 30, 2026 · Filed August 03, 2026

Jointly reported with ADAR1 Capital Management, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	722,419	Last balance in matching sequence After 2026-07-31 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 9 source rows Row 1 · 2026-07-30 · Purchase · Acquired 50,000 · Balance 443,266 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 2 · 2026-07-30 · Purchase · Acquired 20,000 · Balance 463,266 F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 3 · 2026-07-30 · Purchase · Acquired 20,000 · Balance 483,266 F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 4 · 2026-07-30 · Purchase · Acquired 25,000 · Balance 508,266 F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 5 · 2026-07-30 · Purchase · Acquired 100,000 · Balance 608,266 F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 6 · 2026-07-30 · Purchase · Acquired 77,850 · Balance 686,116 F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 7 · 2026-07-31 · Purchase · Acquired 3,300 · Balance 689,416 F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 8 · 2026-07-31 · Purchase · Acquired 25,000 · Balance 714,416 F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 9 · 2026-07-31 · Purchase · Acquired 8,003 · Balance 722,419 F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Rallybio Corp

Report date May 18, 2026 · Filed May 21, 2026

Jointly reported with ADAR1 Capital Management, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	926,352	Last balance in matching sequence After 2026-05-19 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-05-18 · Purchase · Acquired 6,009 · Balance 916,152 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9100 to $14.0000, inclusive. Each Reporting Person undertakes to provide Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 2 · 2026-05-19 · Purchase · Acquired 10,000 · Balance 926,152 F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9350 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Row 3 · 2026-05-19 · Purchase · Acquired 200 · Balance 926,352 F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9100 to $14.0000, inclusive. Each Reporting Person undertakes to provide Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9350 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

TENAX THERAPEUTICS, INC.

Report date September 03, 2026 · Filed September 08, 2026

Jointly reported with ADAR1 Capital Management, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,524,151	Reported balance After 2026-09-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-03 · Purchase · Acquired 900,000 · Balance 6,524,151 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

F3: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Keros Therapeutics, Inc.

Report date October 15, 2025 · Filed October 15, 2025

Jointly reported with ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC

Section 16 reporting ended · disclosed 2025-10-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy ADAR1 Partners, LP	Reported balance After 2025-10-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-10-15 · Sale · Disposed 4,391,237 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Common StockSEC Table I · non-derivative	IndirectBy ADAR1 SPVI, LP	Reported balance After 2025-10-15 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-10-15 · Sale · Disposed 254,669 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Common StockSEC Table I · non-derivative	IndirectBy Spearhead Insurance Solutions IDF, LLC	Reported balance After 2025-10-15 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-10-15 · Sale · Disposed 743,358 · Balance 0 F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP.

F2: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (right to sell) · Derivative	2	$0.00 Strike: $70.00	$0.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 6 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 0 Underlying: Common Stock · 200 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (right to sell) · Derivative	14	$0.00 Strike: $70.00	$0.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 5 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 1,400 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (right to sell) · Derivative	1	$0.00 Strike: $60.00	$0.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · derivative · entry 4 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2025-06-20 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	200	$70.00	$14,000.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 743,358 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	1,400	$70.00	$98,000.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,391,237 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:05 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	100	$60.00	$6,000.00	Disclosure SEC source: 0001104659-25-062092 · tm2518715-1_4seq1.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,392,637 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
May 16, 2025 Filed Jun 12, 2025 16:51 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (obligation to buy) · Derivative	178	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 0 Underlying: Common Stock · 17,800 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
May 16, 2025 Filed Jun 12, 2025 16:51 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (obligation to buy) · Derivative	836	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 83,600 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
May 16, 2025 Filed Jun 12, 2025 16:51 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherPut Option (obligation to buy) · Derivative	300	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001104659-25-058955 · tm2517803-1_4seq1.xml · derivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2025-05-16 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. F2 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCash Settled Total Return Swaps · Derivative	74,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 9 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 50,000 Underlying: Common Stock · 74,333 shares Expires not disclosed F7 · derivative.exercise_price: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · kind: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · shares: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · price: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.exercise_date: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.expiration_date: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · derivative.underlying_shares: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F7 · balance_after: In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCash-Settled Total Return Swaps · Derivative	500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 8 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 124,333 Underlying: Common Stock · 500,000 shares Expires not disclosed F6 · derivative.exercise_price: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · kind: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · shares: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · price: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.exercise_date: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.expiration_date: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · derivative.underlying_shares: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F6 · balance_after: In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCash-Settled Total Return Swaps · Derivative	325,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · derivative · entry 7 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 624,333 Underlying: Common Stock · 325,000 shares Expires not disclosed F5 · derivative.exercise_price: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · kind: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · shares: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · price: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.exercise_date: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.expiration_date: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · derivative.underlying_shares: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F5 · balance_after: In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	74,333	$10.33	$767,859.89	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 5 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,392,737 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	500,000	$10.33	$5,165,000.00	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 4 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 4,318,404 F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	325,000	$9.86	$3,203,525.00	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 3 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 3,818,404 F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $10.60, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	16,365	$9.40	$153,752.45	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 2 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spearhead Insurance Solutions IDF, LLC Disclosed balance after: 743,558 F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:57 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	18,560	$9.40	$174,374.91	Disclosure SEC source: 0001104659-25-034321 · tm2512234-2_4seq1.xml · nonDerivative · entry 1 ADAR1 Capital Management, LLC · CIK 0001940272 · 10% owner ADAR1 Partners, LP · CIK 0001758866 · 10% owner ADAR1 Capital Management GP, LLC · CIK 0001940267 · 10% owner Schneeberger Daniel · CIK 0001861120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ADAR1 Partners, LP Disclosed balance after: 3,493,404 F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive. F1 · ownership.nature: As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP. F8 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.